Article Text

Download PDFPDF
Haematology patients infected with SARS-CoV-2, pretreated with eculizumab or siltuximab, develop oligosymptomatic disease
  1. Sabina Iluta1,
  2. Sergiu Pasca2,
  3. Delia Dima3,
  4. Gabriela Mester3,
  5. Laura Urian1,
  6. Anca Bojan1,
  7. Mihnea Zdrenghea1,
  8. Adrian Trifa1,
  9. Ovidiu Balacescu4,
  10. Ciprian Tomuleasa1,2
  1. 1 Department of Hematology, Iuliu Hatieganu University of Medicine and Pharmacy, Cluj Napoca, Romania
  2. 2 Medfuture Research Center for Advanced Medicine, Iuliu HaTieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj Napoca, Romania
  3. 3 Department of Hematology, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
  4. 4 Department of Genetics, Ion Chiricuta Oncology Institute, Cluj Napoca, Romania
  1. Correspondence to Dr Ciprian Tomuleasa, Iuliu Hagieganu University of Medicine and Pharmacy Faculty of Medicine, Cluj Napoca 400124, Romania; ciprian.tomuleasa{at}

Statistics from

Request Permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

We have read with great interest the publication from Palanques-Pastor and colleagues,1 and due to the interest in this subject we would like to mention that we also observed no SARS-CoV-2 symptoms in a patient with multicentric Castleman’s disease. The patient was a woman diagnosed in her 20s, who initially presented with sweating, fatigue, dyspnoea at medium effort and weight gain. At the clinical exam, the only concerning observation was that the patient presented with abdominal obesity. Aside from this, the patient had normal respiratory, cardiac and digestive examinations. She was negative for the following viruses: HIV, human herpesvirus 8, hepatitis B virus and hepatitis C virus, and received four …

View Full Text


  • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

  • Competing interests None declared.

  • Provenance and peer review Not commissioned; internally peer reviewed.